Latest news with #ZimVie
Yahoo
24-07-2025
- Business
- Yahoo
ZimVie to Be Taken Private by Archimed in $730 Million Buyout Deal
ZimVie (ZIMV) shares surged intraday Monday after the dental implant company agreed to be acquired a
Business Wire
22-07-2025
- Business
- Business Wire
ZIMVIE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ZimVie Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Under the terms of the proposed transaction, shareholders of ZimVie will receive $19.00 in cash for each share of ZimVie that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Yahoo
22-07-2025
- Business
- Yahoo
ARCHIMED to acquire life sciences company ZimVie for $730m
Healthcare investment company ARCHIMED's affiliate is set to acquire ZimVie, a life sciences company focusing on the dental implant market, for an enterprise value of around $730m. According to the definitive agreement signed by the companies, the stockholders of ZimVie will be entitled to a $19.00 cash payment for each outstanding share when the transaction is finalised. The price per share signifies a premium of 99% to ZimVie's 90-day volume-weighted average share price, which stands at $9.57. ZimVie's Board of Directors granted unanimous approval for the transaction, anticipated to be finalised by the end of this year. This is contingent on standard closing conditions, including ZimVie's stockholders' and regulatory bodies' approval. Notably, the agreement is not dependent on financing. ARCHIMED managing partner André-Michel Ballester said: 'We're excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.' Following the acquisition, ZimVie is set to become a private entity. Additionally, ZimVie, with Centerview Partners' assistance, may seek alternative proposals for a 40-day period ending on 29 August 2025, although there is no certainty of a superior offer emerging. ZimVie CEO and board chairman Vafa Jamali said: 'This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years. 'Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.' Centerview Partners is acting as ZimVie's exclusive financial adviser, with Cravath, Swaine & Moore as its legal adviser. Meanwhile, UBS Investment Bank and Latham & Watkins are serving as ARCHIMED's financial and legal advisers, respectively. In 2023, the US Food and Drug Administration (FDA) cleared ZimVie's spinal fixation system, Vital, for use with Brainlab's surgical imaging, planning, and navigation tools. "ARCHIMED to acquire life sciences company ZimVie for $730m" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
22-07-2025
- Business
- Associated Press
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: iTeos Therapeutics, Inc. (NASDAQ: ITOS)'s sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire iTeos for $10.047 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos' product candidates that occurs within six months following the closing. If you are an iTeos shareholder, click here to learn more about your rights and options. ZimVie Inc. (NASDAQ: ZIMV)'s sale to an affiliate of ARCHIMED for $19.00 in cash per share. If you are a ZimVie shareholder, click here to learn more about your rights and options. Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected]. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. One World Trade Center 85th Floor New York, NY 10007 (212) 763-0060 [email protected] [email protected]
Yahoo
21-07-2025
- Business
- Yahoo
ZimVie to Be Taken Private by Archimed in $730 Million Buyout Deal
ZimVie (ZIMV) shares surged intraday Monday after the dental implant company agreed to be acquired a Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
